Overview

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Status:
Not yet recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy and safety of recombinant anti-IL-1β humanized monoclonal antibody injection in Chinese participants with acute gout.

Phase:

Phase 3

Details

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Betamethasone